Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

Learn about the use of GLP-1 agonists for weight loss and health improvement by celebrities like Oprah and Serena Williams.

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

Novo Nordisk A/S (NYSE: NVO) is one of the Most Undervalued International Stocks According to Analysts. On August 19, TD ...

Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

New gene therapies that can come with a one-time cost of more than $2 million also are having an impact, insurance brokers ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.